Type I IFN Signaling Is Essential for Preventing IFN-γ Hyperproduction and Subsequent Deterioration of Antibacterial Immunity during Postinfluenza Pneumococcal Infection.
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
01
12
2021
accepted:
27
04
2022
pubmed:
16
6
2022
medline:
2
7
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Postinfluenza bacterial pneumonia is a significant cause of hospitalization and death in humans. The mechanisms underlying this viral and bacterial synergy remain incompletely understood. Recent evidence indicates that influenza-induced IFNs, particularly type I IFN (IFN-I) and IFN-γ, suppress antibacterial defenses. In this study, we have investigated the relative importance and interplay of IFN-I and IFN-γ pathways in influenza-induced susceptibility to
Identifiants
pubmed: 35705254
pii: jimmunol.2101135
doi: 10.4049/jimmunol.2101135
pmc: PMC9247018
mid: NIHMS1803120
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interferon Type I
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-135Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL118408
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI128527
Pays : United States
Informations de copyright
Copyright © 2022 by The American Association of Immunologists, Inc.
Références
Emerg Infect Dis. 2008 Aug;14(8):1187-92
pubmed: 18680640
mBio. 2019 May 7;10(3):
pubmed: 31064834
J Immunol. 2010 Feb 15;184(4):2048-56
pubmed: 20083661
Front Immunol. 2018 May 28;9:1135
pubmed: 29892288
J Clin Invest. 2009 Jul;119(7):1910-20
pubmed: 19487810
J Immunol. 2021 Sep 1;207(5):1371-1376
pubmed: 34380647
Cell Host Microbe. 2007 Oct 11;2(4):240-9
pubmed: 18005742
Nat Med. 2008 May;14(5):558-64
pubmed: 18438414
Antiviral Res. 2013 Sep;99(3):230-7
pubmed: 23721943
J Immunol. 2018 Jul 1;201(1):134-144
pubmed: 29760191
J Immunol. 2004 Oct 1;173(7):4576-81
pubmed: 15383591
Infect Immun. 2019 Apr 23;87(5):
pubmed: 30804099
Cell Host Microbe. 2010 Feb 18;7(2):103-14
pubmed: 20159617
Eur J Immunol. 2016 Dec;46(12):2778-2788
pubmed: 27701741
Eur J Immunol. 2014 Nov;44(11):3263-72
pubmed: 25091976
J Clin Invest. 2011 Sep;121(9):3657-65
pubmed: 21841308
PLoS Pathog. 2021 Mar 9;17(3):e1009405
pubmed: 33690728
J Immunol. 2018 Feb 15;200(4):1425-1433
pubmed: 29311363
J Immunol. 2013 Aug 1;191(3):1250-9
pubmed: 23804714
J Exp Med. 2008 Feb 18;205(2):323-9
pubmed: 18227219
EMBO Mol Med. 2014 Jan;6(1):120-40
pubmed: 24408967
J Immunol. 2011 Feb 1;186(3):1666-1674
pubmed: 21178015
Am J Physiol Lung Cell Mol Physiol. 2015 Jul 15;309(2):L158-67
pubmed: 26001778
Infect Immun. 2015 Oct;83(10):3764-70
pubmed: 26216421
mBio. 2021 Feb 16;12(1):
pubmed: 33593970
J Immunol. 2010 Jan 15;184(2):877-85
pubmed: 20018611
Mucosal Immunol. 2018 Jan;11(1):209-219
pubmed: 28513592
mBio. 2016 Feb 09;7(1):e01939-15
pubmed: 26861017
J Immunol. 2020 Sep 15;205(6):1601-1607
pubmed: 32796026
MMWR Morb Mortal Wkly Rep. 2009 Sep 4;58(34):941-7
pubmed: 19730406
PLoS Pathog. 2016 Jan 05;12(1):e1005378
pubmed: 26731100
PLoS Pathog. 2013 Mar;9(3):e1003238
pubmed: 23555251
J Immunol. 2013 Sep 1;191(5):2047-52
pubmed: 23964104
mBio. 2016 May 03;7(3):
pubmed: 27143388
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
PLoS Pathog. 2011 Feb;7(2):e1001304
pubmed: 21383977
J Infect Dis. 2008 Oct 1;198(7):962-70
pubmed: 18710327
J Virol. 2012 Nov;86(22):12304-12
pubmed: 22951826